Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
about
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareRepurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Computational analysis and predictive modeling of polymorph descriptors.Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.The discovery and development of rivaroxaban.Pharmacogenomics of the triazole antifungal agent voriconazole.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Repurposing itraconazole as an anticancer agent.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.Repurposing itraconazole for the treatment of cancer.Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.Antimicrobial and antiurease activities of newly synthesized morpholine derivatives containing an azole nucleus.Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.PharmGKB summary: very important pharmacogene information for ABCG2.Synthesis, characterization and antimicrobial evaluation of some new schiff, mannich and acetylenic Mannich bases incorporating a 1,2,4-triazole nucleus.Structure-pharmacokinetic relationship of in vivo rat biliary excretion.Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report.
P2860
Q26851160-D22A3666-7937-4BBB-B656-CBD1AE126135Q34474583-44FBF986-2446-42C0-9DBF-D5683BA1448FQ34871636-59B36A2C-36AC-40C5-B4FC-614A1C244529Q36687860-087C57CA-430C-494C-9F24-C62964871403Q37076348-29E5AA1B-B862-4E37-9EC5-E7D86828D67BQ37857332-59D8ADC9-4F41-4EEC-B7ED-97D0A42DE31AQ37892536-234E93A0-FC3E-47D2-84E7-239EE656F7EAQ37904672-52E1106D-ED40-41A4-8C7A-4153DE331CF6Q38082728-F4E41409-2DC7-4C50-AD4F-A672228466F4Q38633691-4853EBCD-5C54-4F49-9D79-E06C60E09CC2Q38775809-A7F3F697-8FE5-4643-8730-7B09EE455BF8Q40746038-CDC85FB8-1392-4894-BCF9-60C9B1169016Q41613808-13790834-9917-428F-AAAA-4826850CF6E0Q41904888-CF178488-2C93-4DB1-AC7C-EE6ADA104257Q41980730-ECD3DEB6-6AF3-45D6-99C1-EA8385EF7195Q45873564-F3835549-F990-4D06-AEE0-C7598DA2C6DEQ46018199-162C3EDF-612E-424E-9348-B1DD4F37BF25Q46188048-3ABCD1EC-BDEB-4468-968B-3BADD96715FCQ46696627-CA259653-3174-4DA8-BC2C-1BE38190B0F0Q47664190-B0DA6D5A-FB8C-454A-B817-1ECF1AD890FDQ48251035-96300579-4850-44A6-84CD-CD80555918A7Q52721223-1DE51FA8-A805-4434-994E-2136A201CD5FQ55489012-9A89A4E5-DB79-4528-A831-3F3933EADD83
P2860
Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Interactions of azole antifung ...... cer resistance protein (BCRP).
@en
type
label
Interactions of azole antifung ...... cer resistance protein (BCRP).
@en
prefLabel
Interactions of azole antifung ...... cer resistance protein (BCRP).
@en
P2093
P356
P1476
Interactions of azole antifung ...... cer resistance protein (BCRP).
@en
P2093
Anshul Gupta
Jashvant D Unadkat
Qingcheng Mao
P304
P356
10.1002/JPS.20963
P407
P577
2007-12-01T00:00:00Z